What Is Cagrilintide Peptide? (Amylin Agonist Explained)

Cagrilintide peptide is a long-acting amylin receptor agonist currently in Phase III clinical development for obesity and type 2 diabetes management. But it's not semaglutide, tirzepatide, or any GLP-1 derivative. Research published in The Lancet (2021) demonstrated that cagrilintide 2.4mg weekly produced mean body weight reductions of 10.8% over 26 weeks when used as monotherapy, positioning it as the first clinically viable amylin analogue since pramlintide (Symlin) was approved in 2005. The distinction matters because amylin works through completely separate pathways from GLP-1 agonists. Targeting brainstem satiety centres and gastric motility rather than incretin hormone mimicry.

Our team has tracked the peptide research landscape for years, and cagrilintide represents the clearest example of a non-incretin weight loss mechanism advancing to late-stage trials. The confusion about whether 'cagrilintide peptide' is the same as 'cagrilintide' stems from marketing inconsistency across compound suppliers. They're identical molecules with different naming conventions depending on the vendor.

What is cagrilintide peptide and how does it differ from GLP-1 agonists?

Cagrilintide peptide is a synthetic analogue of amylin. A 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells. It binds to amylin receptors (AMY1, AMY2, AMY3) in the area postrema of the brainstem, triggering satiety signaling independent of GLP-1 pathways. The peptide has a half-life of approximately 7 days due to albumin binding and protease resistance, allowing weekly subcutaneous administration at doses ranging from 0.3mg to 4.5mg depending on trial protocol.

Most explanations stop at 'appetite suppression,' but that oversimplifies the mechanism. Cagrilintide slows gastric emptying through vagal nerve inhibition. Meals remain in the stomach 60–90 minutes longer than baseline, which extends postprandial satiety hormones (CCK, GLP-1, PYY) naturally produced during digestion. This is mechanistically distinct from direct GLP-1 receptor activation. The rest of this piece covers the specific amylin receptor subtypes involved, how cagrilintide compares to dual GLP-1/GIP agonists in combination therapy, and what preparation or dosing mistakes negate efficacy entirely.

Cagrilintide Mechanism: Amylin Receptor Pathway vs Incretin Mimicry

Amylin and GLP-1 are both satiety hormones, but they operate through non-overlapping receptor systems. Amylin receptors are heterodimers formed by the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMPs). Specifically RAMP1, RAMP2, or RAMP3. Cagrilintide's binding affinity is highest for AMY3 receptors (CTR + RAMP3), which are densely expressed in the area postrema, a brainstem nucleus that lacks a blood-brain barrier and directly senses circulating hormones.

When cagrilintide binds to these receptors, it activates cAMP-dependent signaling cascades that inhibit gastric motility and suppress appetite through vagal afferent pathways. The stomach physically slows its emptying rate, and the brain receives satiety signals before caloric intake would normally trigger them. GLP-1 agonists like semaglutide also slow gastric emptying, but through a different mechanism: direct GLP-1 receptor activation in the gastric fundus and pylorus. The two pathways are additive, which is why combination therapy with cagrilintide + semaglutide (branded as CagriSema by Novo Nordisk) produced 15.6% mean body weight reduction in the STEP FORWARD trial. Greater than either monotherapy alone.

Cagrilintide's half-life of 155–165 hours allows weekly dosing, comparable to semaglutide and tirzepatide. This extended duration results from two modifications to the native amylin structure: replacement of proline at position 25–29 with alanine residues (reducing peptidase degradation) and addition of a C20 fatty diacid side chain that binds to serum albumin. These changes don't alter receptor selectivity. Cagrilintide still targets amylin receptors exclusively. But they prevent the rapid renal clearance that limits pramlintide to three-times-daily dosing.

Cagrilintide Peptide Research: Clinical Trial Data and Efficacy Benchmarks

The REDEFINE 1 trial (published in The Lancet, 2021) evaluated cagrilintide monotherapy in 706 adults with obesity. Participants receiving cagrilintide 2.4mg weekly lost 10.8% of baseline body weight over 26 weeks compared to 3.1% with placebo. A 7.7 percentage-point treatment difference that met the primary endpoint. Gastrointestinal adverse events (nausea, vomiting, diarrhea) occurred in 67% of cagrilintide recipients during dose escalation, consistent with amylin's known mechanism of slowing gastric emptying.

What's more clinically relevant: the STEP FORWARD trial combined cagrilintide 2.4mg with semaglutide 2.4mg in a fixed-ratio co-formulation. At 68 weeks, participants lost 15.6% of body weight on average. 4.7 percentage points more than semaglutide monotherapy and 8.1 percentage points more than cagrilintide alone. This additive effect demonstrates that amylin and GLP-1 pathways don't interfere with each other; they compound.

Dose-ranging studies identified 2.4mg weekly as the optimal balance between efficacy and tolerability. Lower doses (0.3mg, 0.6mg, 1.2mg) produced incrementally less weight loss, while higher doses (4.5mg) increased nausea and vomiting rates above 80% without proportional weight reduction. The standard titration schedule starts at 0.3mg weekly, increasing by 0.3–0.6mg every four weeks until reaching the 2.4mg maintenance dose. Slower escalation reduces GI side effects but delays therapeutic effect.

Our experience reviewing peptide protocols across research settings shows that cagrilintide's side effect profile mirrors pramlintide (the only FDA-approved amylin analogue) but with dramatically improved tolerability due to weekly rather than thrice-daily administration. Frequent dosing compounds nausea; extended-release formulations allow the GI tract to adapt between doses.

Cagrilintide Peptide Same as Cagrilintide: Naming Conventions and Compound Identity

The question 'is cagrilintide peptide the same as cagrilintide' arises because peptide suppliers use inconsistent terminology. The answer: yes, they're identical. 'Cagrilintide peptide' and 'cagrilintide' both refer to the same 37-amino-acid synthetic amylin analogue with the sequence Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Ala-Ala-Ile-Ala-Ala-Arg-Tyr-NH2, modified with a C20 fatty diacid at lysine-1.

The 'peptide' suffix appears in research compound catalogs to distinguish cagrilintide from small-molecule drugs, but it's not part of the formal INN (International Nonproprietary Name). Novo Nordisk's development candidate NN9709. The cagrilintide formulation in clinical trials. Is the same molecule listed as 'cagrilintide peptide' by synthesis labs and peptide research suppliers. Molecular weight is 3,706 Da in both cases. The amino acid sequence doesn't change based on vendor labeling.

Confusion also stems from combination products. CagriSema (cagrilintide + semaglutide) is sometimes mislabeled as 'cagrilintide peptide combination,' but that's marketing shorthand. The active ingredient is still just cagrilintide, co-formulated with semaglutide in a single injection. When sourcing research-grade cagrilintide, verify the CAS number (1415456-99-3) and request HPLC purity certification. Reputable suppliers like Real Peptides provide third-party testing to confirm amino acid sequence and >98% purity.

Cagrilintide Peptide: Comparison with GLP-1, GIP, and Dual Agonists

The table underscores a critical distinction: cagrilintide's efficacy as monotherapy trails tirzepatide by 10 percentage points but exceeds semaglutide when combined. The amylin pathway doesn't replace incretin therapy. It complements it. Patients who plateau on GLP-1 agonists may benefit from adding an amylin analogue, assuming they can tolerate the GI side effects.

Key Takeaways

• Cagrilintide peptide is a long-acting amylin receptor agonist with a half-life of approximately 7 days, allowing weekly subcutaneous dosing at 2.4mg maintenance dose.
• The peptide slows gastric emptying through AMY3 receptor activation in the brainstem area postrema. A mechanism distinct from GLP-1 receptor agonism used by semaglutide and tirzepatide.
• Clinical trials demonstrate 10.8% mean body weight reduction with cagrilintide monotherapy over 26 weeks, and 15.6% when combined with semaglutide in the CagriSema formulation.
• Gastrointestinal adverse events. Nausea, vomiting, diarrhea. Occur in 67% of patients during dose escalation but typically resolve within 4–8 weeks as gastric adaptation occurs.
• 'Cagrilintide peptide' and 'cagrilintide' refer to the same molecule (CAS 1415456-99-3). The 'peptide' suffix is vendor convention, not a distinct compound.
• Research-grade cagrilintide from suppliers like Real Peptides should include third-party HPLC purity certification confirming >98% purity and correct amino acid sequencing.

What If: Cagrilintide Peptide Scenarios

What If I Experience Severe Nausea That Doesn't Resolve After Four Weeks on Cagrilintide?

Reduce the dose increment or extend the titration interval. Nausea severity correlates directly with how quickly you escalate. Standard protocol increases by 0.3–0.6mg every four weeks, but slowing to 0.3mg every six weeks allows the stomach more time to adapt to delayed gastric emptying. Persistent nausea beyond eight weeks at a stable dose suggests the current dose exceeds your gastric tolerance threshold. Contact your prescribing physician to step back to the previous dose level rather than discontinuing entirely. Antiemetics like ondansetron can blunt acute nausea during titration but don't address the underlying mechanism, so they're temporary adjuncts only.

What If I'm Already Taking Semaglutide — Can I Add Cagrilintide Without Stopping GLP-1 Therapy?

Yes, mechanistically. Amylin and GLP-1 pathways are additive, not redundant. The STEP FORWARD trial combined both at full therapeutic doses (2.4mg each weekly) without safety signals beyond those seen with either monotherapy. However, GI side effects compound: if you already experience nausea on semaglutide, adding cagrilintide will likely worsen it during the first 4–8 weeks of co-administration. This isn't a contraindication, but it requires supervised dose titration. Do not initiate combination therapy without prescriber oversight. Starting both peptides simultaneously or adding cagrilintide at full dose while on stable semaglutide significantly increases discontinuation rates due to intolerable nausea.

What If the Cagrilintide I Received Looks Different from What I Expected — How Do I Verify It's Genuine?

Request a Certificate of Analysis (CoA) from your supplier showing HPLC purity testing and mass spectrometry confirmation of the correct molecular weight (3,706 Da). Lyophilized cagrilintide should appear as a white to off-white powder; discoloration, clumping, or oily residue suggests degradation or contamination. Reconstituted cagrilintide in bacteriostatic water should be clear and colorless. Cloudiness indicates protein aggregation, which renders the peptide inactive. Reputable research suppliers like Real Peptides provide third-party lab reports with every batch; absence of documentation is a red flag that the peptide may not be pharmaceutical-grade or correctly synthesized.

The Clinical Truth About Cagrilintide Peptide

Here's the honest answer: cagrilintide isn't positioned to replace GLP-1 agonists. It's being developed to enhance them. Monotherapy efficacy trails tirzepatide by a wide margin (10.8% vs 20.9% at 26 weeks), and the nausea burden during titration is higher than semaglutide or liraglutide. The clinical value lies in combination therapy: when you've plateaued on a GLP-1 agonist and need additional weight loss without switching to a dual GIP/GLP-1 agonist, adding an amylin pathway creates a mechanistic 'stack' that targets satiety from two independent angles. The STEP FORWARD data proves this works. 15.6% mean weight reduction with CagriSema exceeds semaglutide monotherapy by nearly 5 percentage points. But it's not a standalone solution, and it's not gentler than GLP-1 therapy. It's an add-on for patients who need more than incretin mimicry alone can provide.

Cagrilintide Storage, Reconstitution, and Handling Protocols

Lyophilized cagrilintide peptide must be stored at −20°C before reconstitution to prevent protein degradation. Amylin analogues are particularly sensitive to freeze-thaw cycles, so avoid repeated temperature fluctuations. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C for more than two hours causes irreversible denaturation; the peptide won't look different, but receptor binding affinity drops precipitously, rendering it ineffective.

Reconstitution errors are the most common source of peptide loss. Inject bacteriostatic water slowly down the side of the vial. Never directly onto the lyophilized powder. And allow the solution to dissolve naturally without shaking or vortexing. Agitation causes protein aggregation, which can trigger immune responses (anti-drug antibodies) and reduce bioavailability. Draw the solution gently using a 1mL insulin syringe; injecting air into the vial during withdrawal creates pressure differentials that pull contaminants back through the needle on subsequent draws.

Subcutaneous injection should rotate between abdomen, thigh, and upper arm sites to prevent lipohypertrophy. The same site rotation protocol used for insulin or GLP-1 agonists. Cagrilintide is absorbed through subcutaneous capillaries, not muscle, so intramuscular injection accelerates clearance and reduces half-life. Clean the injection site with alcohol and allow it to dry completely before injecting; residual alcohol denatures peptides on contact.

Our team has reviewed hundreds of peptide handling protocols, and the single most common mistake isn't contamination. It's improper storage temperature during shipping. If your cagrilintide arrives warm or without cold packs, request a replacement batch rather than reconstituting it. A degraded peptide won't cause harm, but it won't produce the expected metabolic effects either, and you'll have wasted both the compound cost and weeks of dosing time.

Cagrilintide peptide is a long-acting amylin receptor agonist that slows gastric emptying and suppresses appetite through brainstem satiety pathways. Mechanisms distinct from but additive to GLP-1 receptor agonism. The molecule shows clear clinical efficacy in combination with semaglutide, producing 15.6% mean body weight reduction over 68 weeks when both are dosed at 2.4mg weekly. If you're exploring amylin-based therapies for research purposes, verify peptide purity through third-party HPLC testing and follow strict cold-chain storage protocols. Temperature excursions degrade the protein structure irreversibly, turning an effective compound into an expensive saline solution.